Therapy-Related Myelodysplastic Syndrome Recruiting Phase 2 Trials for Clofarabine (DB00631)

IndicationStatusPhase
DBCOND0079186 (Therapy-Related Myelodysplastic Syndrome)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02727803Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple MyelomaTreatment